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Abstract
Six novel members of the IL-1 family of cytokines were recently
identified, primarily through the use of DNA database searches
for IL-1 homologues, and were named IL-1F5 to IL-1F10. In the
present study, we investigated the effect of IL-1F8 on primary
human joint cells, and examined the expression of the new IL-1
family members in human and mouse joints. Human synovial
fibroblasts (hSFs) and human articular chondrocytes (hACs)
expressed the IL-1F8 receptor (IL-1Rrp2) and produced pro-
inflammatory mediators in response to recombinant IL-1F8. IL-
1F8 mRNA expression was increased in hSFs upon stimulation
with proinflammatory cytokines, whereas in hACs IL-1F8 mRNA
expression was constitutive. However, IL-1F8 protein was
undetectable in hSF and hAC culture supernatants.
Furthermore, although IL-1β protein levels were increased in
inflamed human and mouse joint tissue, IL-1F8 protein levels
were not. IL-1F8 levels in synovial fluids were similar to or lower
than those in matched serum samples, suggesting that the joint
itself is not a major source of IL-1F8. Serum levels of IL-1F8
were similar in healthy donors, and patients with rheumatoid
arthritis, osteoarthritis and septic shock, and did not correlate
with inflammatory status. Interestingly however, we observed
high IL-1F8 levels in several serum samples in all groups. In
conclusion, IL-1F8 exerts proinflammatory effects in primary
human joint cells. Joint and serum IL-1F8 protein levels did not
correlate with inflammation, but they were high in some human
serum samples tested, including samples from patients with
rheumatoid arthritis. It remains to be determined whether
circulating IL-1F8 can contribute to joint inflammation in
rheumatoid arthritis.
Introduction
Until recently, the IL-1 family of cytokines included four mem-
bers, with three having pro-inflammatory effects (IL-1α, IL-1β
and IL-18) and the fourth member being an IL-1 receptor
antagonist (IL-1Ra). IL-1 family members exert their effects
through binding to receptors that belong to the IL-1 receptor
(IL-1R) family. IL-1α and IL-1β bind to the type I IL-1 receptor
(IL-1RI), resulting in recruitment of the IL-1 receptor accessory
protein (IL-1RAcP), which is necessary for signal transduction.
IL-1Ra negatively regulates IL-1 activity by competing with IL-
1 for binding to IL-1RI. Binding of IL-1Ra to IL-1RI does not
allow the recruitment of the accessory protein, and therefore it
does not generate a signal (for review see [1]). IL-18 activity is
mediated through its binding to other members of the same
BSA = bovine serum albumin; CIA = collagen-induced arthritis; ELISA = enzyme-linked immunosorbent assay; FCS = foetal calf serum; hAC = human 
articular chondrocyte; hSF = human synovial fibroblast; IL = interleukin; IL-1Ra = IL-1 receptor antagonist; IL-1RacP = IL-1 receptor accessory pro-
tein; IL-1Rrp2 = IL-1 receptor related protein 2; OA = osteoarthritis; PBS = phosphate-buffered saline; PMA = phorbol 13-myristate 12-acetate; RA 
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receptor family, namely IL-18 receptor (IL-18R) and the IL-18R
accessory protein [2].
Six new members of the IL-1 family were recently identified,
primarily through the use of DNA database searches for homo-
logues of IL-1 [3-10]. These proteins were named IL-1F5 to IL-
1F10 [11]. In humans all of the new genes map to less than
300 kb of chromosome 2, where they are flanked by IL-1α, IL-
1β and IL-1Ra. Sequence alignments and some physical data
predict that the secondary structure of all of the new homo-
logues is characterized by a 12-stranded β-trefoil structure
shared with IL-1α, IL-1β and IL-1Ra [12]. IL-1F5 was recently
characterized at high resolution [13].
Expression patterns and the biological functions of the six new
IL-1 family members have not yet been well characterized. It
has been reported that IL-1F7 forms a complex with IL-18
binding protein, which might bind to and sequester IL-18R
accessory protein, thus inhibiting the effects of IL-18 [14]. In
addition, adenoviral overexpression of IL-1F7 in mouse was
shown to have anti-tumour effects by an undefined mecha-
nism, even though rodents appear to lack the IL-1F7 gene
[15]. IL-1F10 has been described as a low affinity, nonagonis-
tic ligand for IL-1RI [7]. Debets and coworkers [5] have shown
that IL-1F9 activates nuclear factor-κB in Jurkat cells that over-
express IL-1 receptor related protein 2 (IL-1Rrp2) and that this
activation is blocked by IL-1F5, suggesting that IL-1F5 might
be an IL-1F9 antagonist. Recently, Towne and coworkers [16]
reported that, in addition to IL-1F9, IL-1F6 and IL-1F8 also
activated nuclear factor-κB and showed that signalling
required IL-1RAcP. Inhibition of IL-1F6-, IL-1F8-, or IL-1F9-
mediated activation of nuclear factor-κB by IL-1F5 was
described as incomplete and inconsistent. In that study, using
an epithelial cell line that expresses both IL-1Rrp2 and IL-
1RAcP, the three homologues activated an IL-8 promoter
reporter gene construct and secretion of IL-6, even though the
required IL-1F concentrations were much higher than those
necessary for IL-1β activity.
Rheumatoid arthritis (RA) is characterized by chronic inflam-
mation of the synovial tissue in multiple joints that leads to joint
destruction. Major hypotheses have involved dysfunction of
antigen-presenting cells; B cells and autoantibody production;
T cell reactivity; and, recently, cytokines (for review, see [17]).
Indeed, it is widely recognized that tumour necrosis factor
(TNF)-α and IL-1 play key roles in mediating the pathophysio-
logical processes that underlie the inflammation and tissue
destruction that occur in RA. The role of the four 'classical' IL-
1 family members (for instance, IL-1α, IL-1β, IL-1Ra and IL-18)
in the pathogenesis and development of RA was illustrated in
mouse models of arthritis, particularly by the spontaneous
arthritis that develops in IL-1α transgenic mice [18] as well as
in IL-1Ra deficient mice [19]. It was also highlighted by the sig-
nificant protection against collagen-induced arthritis (CIA) that
characterizes overexpression of IL-1Ra [20,21] and genetic
deficiency in IL-1α, IL-1β [22], or IL-18 [23].
In the present study we investigated the effects of the new IL-
1 family member IL-1F8 on primary human synovial fibroblasts
(hSFs) and human articular chondrocytes (hACs), and exam-
ined the expression of the new IL-1 homologues in human and
mouse joints.
Materials and methods
Materials
Cell culture reagents were obtained from Invitrogen Life Tech-
nologies (Basel, Switzerland). Recombinant human IL-1β,
recombinant human IL-1F8 and goat polyclonal anti-human IL-
1Rrp2, as well as anti-human and anti-mouse IL-1F8 antibod-
ies, were purchased from R&D Systems (Abington, UK). Trizol
reagent and dNTP were obtained from Invitrogen. Taq DNA
polymerase was obtained from Qiagen AG (Basel, Switzer-
land). DNase I, AMV-RT (avian myeloblastosis virus-reverse
transcriptase), random primers, recombinant ribonuclease
inhibitor and DNA 100 bp ladder were purchased from
Promega (Wallisellen, Switzerland). DNA Master SYBR green
I or Fast Start DNA Master SYBR green I kits were obtained
from Roche Molecular Biochemicals (Rotkreuz, Swizerland).
Cell culture
Synovium and articular cartilage were obtained from patients
undergoing joint replacement (knee or hip prosthetic surgery)
for osteoarthritis (OA) or broken femoral neck (normal adult
articular cartilage). hSFs and hACs were isolated by colla-
genase digestion, as reported previously [24], and cultured in
Dulbecco's modified Eagle medium supplemented with l-
glutamine, streptomycin, penicillin and 10% heat-inactivated
foetal calf serum (FCS) at 37°C in a humidified atmosphere
containing 5% CO2. Primary hACs were used directly after
isolation from cartilage and hSFs were used between pas-
sages 2 and 8. To reduce the nonspecific effects of agonists
present in FCS, cells were incubated overnight in low-serum
(0.5% FCS) medium before the various treatments.
RNA isolation
For RNA isolation, hSFs and hACs were seeded in 25 or 75
cm2 flasks. After the indicated incubation times, media were
removed and cells were lyzed in Trizol. Total RNA was pre-
pared according to the manufacturer's instructions. Briefly,
homogenization of tissues in Trizol was followed by centrifuga-
tion at 10,000 rpm (4°C) for 15 minutes in the presence of
chloroform. The upper aqueous phase was collected and total
RNA was precipitated by addition of isopropanol and centrifu-
gation at 7,500 rpm (4°C) for 5 minutes. RNA pellets were
washed with 75% ethanol, dried, reconstituted with sterile
water and quantified by spectrometry.Available online http://arthritis-research.com/content/8/3/R80
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Reverse transcription and polymerase chain reaction
For analysis of mRNA levels by RT-PCR and real-time PCR, 1–
3 µg total RNA were used. After DNase I digestion, RNA sam-
ples were reverse transcribed using AMV-RT (avian myelob-
lastosis virus-reverse transcriptase) and random primers in a
total volume of 30–50 µl. Template cDNAs (2.5 µl) were
amplified in a typical 25 µl PCR reaction containing 20 mmol/
l Tris-HCl (pH 8.4), 50 mmol/l KCl, 1 µmol/l of the respective
primers (Table 1), 2 mmol/l MgCl2, 200 µmol/l dNTP and 2.5
units Taq DNA polymerase. The absence of DNA contamina-
tion in RNA preparations was tested by including RNA sam-
ples that had not been reverse transcribed. Amplifications
were carried out in an Eppendorf Master Cycler (Dr. Vaudaux
AG, Schonenbuch, Switzerland) under the following condi-
tions: denaturation for 3 minutes at 94°C followed by cycles of
30 seconds denaturation at 94°C, 30 seconds annealing at
the primer-specific temperature, and 45 seconds elongation at
72°C. Amplifications of IL-1Rrp2 (primer pair A) and IL-1F8
were performed with 45 cycles, whereas amplification of β-
actin was performed with 25 cycles. PCR products were visu-
alized on 2% agarose gels containing ethidium bromide. All
PCR products were cloned into the pCRII-TOPO® vector (Life
Technologies) and their identity was checked by sequencing.
Quantitative real-time polymerase chain reaction 
analysis
Expression of 28S ribosomal RNA, human IL-1Rrp2 (primer
pair B), IL-1F8 and IL-1β mRNAs was determined by quantita-
tive real-time PCR on reverse-transcribed samples using a
light cycler (Roche Diagnostics, Rotkreuz, Swizerland) with
the DNA Master SYBR green I or Fast Start DNA Master
SYBR green I kits as appropriate. Template cDNAs (2 µl) were
amplified in a typical 10 µl PCR reaction containing 0.25
µmol/l of the respective primers (Table 1). The absence of
DNA contamination in RNA preparations was tested by includ-
ing RNA samples that had not been reverse transcribed.
Primer sequences and conditions for each PCR reaction are
detailed in Table 1. Expression of IL-1Rrp2, IL-1F8, or IL-1β
mRNA was corrected for 28S ribosomal RNA levels.
Preparation of human IL-1F8 and IL-1F5 recombinant 
proteins
Recombinant human IL-1F8 and IL-1F5 were produced in
Escherichia coli, as previously reported [3]. To remove endo-
toxin contamination, protein samples were treated with poly-
myxin B-agarose beads (Sigma, Buchs, Switzerland).
Moreover, in order to check that the effects of IL-1F8 were due
to the protein itself and not to endotoxin contamination, in
some experiments IL-1F8 was heat-inactivated at 95°C for 5
minutes before use. Commercial human recombinant IL-1F8
(R&D Systems) was used for comparison in some experiments
and similar data were obtained with our recombinant protein
and with commercial IL-1F8.
Determination of IL-6, IL-8 and nitric oxide levels
For determination of IL-6, IL-8 and nitric oxide production,
hSFs and primary hACs were plated in 96-well plates at a den-
sity of 40,000 cells per well. Cells were treated for 48 hours
with the indicated concentrations of IL-1β, IL-1F5 and/or IL-
1F8. In some experiments cells were preincubated for 1 hour
with anti-IL-1Rrp2 antibodies (10 µg/ml) before stimulation
with IL-1F8 or IL-1β. Levels of IL-6 and IL-8 in cell superna-
tants, as well as IL-6 levels in human serum, were assessed
using enzyme-linked immunosorbent assay (ELISA) kits from
R&D Systems. Production of nitric oxide was assessed, as
Table 1
Summary of primers used
cDNA Forward and reverse primers Ta (°C) Product (bp) GenBank
IL-1Rrp2 (A) F: 5'-AGCAAAATCCCAGTGTCCAAA-3' 60 291 [AF284434]
R: 5'-ACCCAAAACACAACTCTTCGG-3'
IL-1Rrp2 (B) F: 5'-AGCAAAATCCCAGTGTCCAAA-3' 60 147 [AF284434]
R: 5'-GGTTTACATGTATTCTATGACAG-3'
IL-1F8 F: 5'-ACCAAGGAGAGAGGCATAACTAAT-3' 60 147 [NM173178]
R: 5'-AGTGAACTCAGTCGCATAATGATC-3'
IL-1β F: 5'-GCTGAGGAAGATGCTGGTTC-3' 57 146 [NM000756]
R: 5'-GTGATCGTACAGGTGCATCG-3'
β-actin F: 5'-CCAAGGCCAACCGCGAGAAGATGAC-3' 55 579 [M10277]
R: 5'-AGGGTACATGGTGGTGCCGCCAGAC-3'
28S F: 5'-TTGAAAATCCGCGGGAGA-3' 54 100 [U13369]
R: 5'-ACATTGTTCCAACATGCCAG-3'
Shown are the primer sequences, annealing temperatures (Ta), lengths of the corresponding PCR products, and GenBank accession numbers of 
the DNA sequences. F, forward; IL, interleukin; IL-1Rrp2, IL-1 receptor related protein 2; R, reverse; PCR, polymerase chain reaction.Arthritis Research & Therapy    Vol 8 No 3    Magne et al.
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previously described [24], by the Griess reaction using a
NaNO2 standard.
Human and mouse tissue samples
Synovial biopsies from patients with OA or inflammatory
arthritides (two patients with RA, one with Lyme disease, one
with sacroid arthritis and one with seronegative arthritis) were
obtained by knee arthroscopy. All samples were immediately
frozen in liquid nitrogen. Samples were obtained after appro-
priate informed consent, and their use for research was
approved by the Ethics Committee of the University Hospital
of Geneva.
For induction of CIA, male DBA/1 mice aged between 8 and
10 weeks (Janvier, Le Genest-St-Isle, France) were immunized
with 100 µg native bovine collagen type II (Morwell Diagnos-
tics, Zumikon, Switzerland), emulsified in complete Freund's
adjuvant containing 5 mg/ml Mycobacterium tuberculosis
(Difco, Basel, Switzerland), by intradermal injection at the base
of tail. On day 21, a booster injection of 100 µg collagen type
II in incomplete Freund's adjuvant was given at the base of the
tail. From day 15 after the first immunization onward, mice
were examined daily for the onset of clinical arthritis. Mice
were killed at various time points after disease onset and
arthritic knees were removed and immediately frozen in liquid
nitrogen. Control knees were obtained from naïve DBA/1 mice
and from immunized DBA/1 mice without clinical signs of
arthritis. Skin was obtained from phorbol 13-myristate 12-ace-
tate (PMA; Sigma, Buchs, Switzerland) treated and control
DBA/1 mice. PMA (1 µg in 200 µl acetone), or acetone (200
µl) for control mice, was applied to the dorsal surfaces of
shaved mice. Application of PMA plus acetone or acetone
alone was repeated 24 and 48 hours later. Mice were killed 48
hours after the last application and small pieces of skin were
immediately frozen in liquid nitrogen. Institutional approval was
obtained for all animal experiments.
Determination of IL-1F8 protein levels by enzyme-linked 
immunosorbent assay
For determination of IL-1F8 production, hSFs and primary
hACs were plated in 96-well plates at a density of 40,000 cells
per well. Cells were treated (or not treated) for 48 or 72 hours
Figure 1
IL-1Rrp2 expression by hSFs and hACs IL-1Rrp2 expression by hSFs and hACs. The left panels show a RT-PCR analyses of IL-1Rrp2 expression by (a) hSFs and (b) hACs treated or not 
treated for 8 hours by IL-1β (1 ng/ml) and/or TNF-α (10 ng/ml), as detailed under Materials and method and in Table 1. The images show represent-
ative agarose gel electrophoresis of PCR products. The right panels show real-time PCR analysis of IL-1Rrp2 mRNA levels in hSFs and hACs stim-
ulated (black columns) or not stimulated (white columns) for 8 hours with IL-1β (1 ng/ml) and TNF-α (10 ng/ml). The amount of 28S rRNA was 
monitored as an internal control. The expression of IL-1Rrp2 mRNA was corrected for 28S rRNA levels and the IL-1Rrp2/28S ratios were normal-
ized to the maximal value observed in each experiment, which was set to 100%. The results shown represent the mean ± standard error of data 
obtained with samples from three (hSFs) or four (hACs) independent cultures. IL, interleukin; IL-1Rrp2, IL-1 receptor related protein 2; hAC, human 
articular chondrocyte; hSF, human synovial fibroblast; RT-PCR, reverse transcriptase polymerase chain reaction; TNF, tumour necrosis factor.Available online http://arthritis-research.com/content/8/3/R80
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with 1 ng/ml IL-1β before supernatants were collected.
Human and mouse tissue samples were homogenized in ice-
cold TNT buffer (50 mmol/l Tris [pH 7.4], 150 mmol/l NaCl, 1
mmol/l PMSF, 0.5% Triton X-100) and the lysates were
cleared by centrifugation at 13,000 rpm (4°) for 15 minutes.
Protein concentration in the lysates was assessed using the
Biorad DC protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA). Human serum and synovial fluid samples were
obtained from patients with RA or OA, and control serum was
obtained from healthy blood donors. Serum samples from
patients with septic shock were kindly provided by Dr Pugin
(Department of Intensive Care, University Hospital of Geneva,
Geneva, Switzerland). For determination of IL-1F8 levels in
culture supernatants, human tissue lysates, human serum or
synovial fluids, 96-well plates were coated with a polyclonal
anti-human IL-1F8 antibody (R&D Systems), diluted to 1 µg/ml
in phosphate-buffered saline (PBS). Wells were then washed
with PBS containing 0.05% Tween-20 and blocked with 1%
bovine serum albumin (BSA) in PBS. Samples were applied to
the wells for two hours at room temperature. After washing, a
biotin-conjugated polyclonal anti-human IL-1F8 antibody (R&D
Systems) was added at a dilution of 1/1000 in PBS and 1%
BSA, and incubated for 2 hours at room temperature. Bound
antibody was detected by incubation with streptavidin-horse-
radish peroxidase (dilution 1/1000 in PBS and 1% BSA) for
20 minutes. Colour was developed using tetramethylbenzidine
and H2O2, the reaction was stopped with H2SO4 2N, and opti-
cal density was assessed at 450 nm. Recombinant human IL-
F8 was used for the standard curve. To detect mouse IL-1F8,
a similar ELISA was set up using a polyclonal anti-mouse IL-
1F8 antibody, a biotin-conjugated polyclonal anti-mouse IL-
1F8 antibody and recombinant mouse IL-1F8 (R&D Systems).
The detection limit of these assays was 19 pg/ml.
Statistical analysis
The significance of differences was calculated by analysis of
variance or Mann-Whitney test as appropriate. A difference
between experimental groups was considered statistically sig-
nificant when the P value was below 0.05.
Results
As a first approach to investigate expression of new IL-1 family
members during arthritis, we examined IL-1F5 to IL-1F10
mRNA expression by RT-PCR in joints of mice with CIA and in
synovial biopsies from patients with RA or OA. IL-1F8 was the
only new IL-1 family member for which we detected mRNA
expression both in human synovial biopsies and in mouse
joints. In addition, we also observed IL-1F9 mRNA expression
in mouse joints, whereas expression of IL-1F6 and IL-1F7
mRNA was detected in some human synovial samples (data
not shown).
A recent study [16] reported that IL-1F8 signalling requires the
presence of both IL-1Rrp2 and IL-1RAcP. Therefore, we inves-
tigated IL-1Rrp2 mRNA expression by hSFs and hACs,
because IL-1RAcP expression in these cells has already been
reported [25] and is further demonstrated by their well estab-
lished responsiveness to IL-1β. As shown in Figure 1, both
hSFs and hACs expressed basal levels of IL-1Rrp2 mRNA,
which were not upregulated by IL-1β and/or TNF-α. In con-
trast, we did not observe IL-1Rrp2 expression in THP-1 and
Jurkat cell lines (data not shown), confirming previous findings
[16,25].
Because hSFs and hACs express IL-1Rrp2 mRNA, we
hypothesized that these cells should be able to respond to IL-
1F8 without need for receptor over-expression. As indicated
by Figure 2, IL-1F8 stimulated both IL-6 and IL-8 production in
hSFs and hACs. The response was stronger in hACs, with a
significant increase in IL-6 production with 500 ng/ml of IL-
1F8. In addition, IL-1F8 also stimulated nitric oxide production
by hACs (Figure 2e), suggesting that its effects might be sim-
ilar to those exhibited by IL-1β. There was no synergy between
IL-1β and IL-1F8 for the stimulation of IL-6 production by
hACs, and the effect of 5 µg/ml IL-1F8 was additive with that
of low doses of IL-1β (1–10 pg/ml; data not shown). Further-
more, the effects of IL-1F8 were indeed due to the protein
itself and not to endotoxin contamination because heat-inacti-
vated IL-1F8 failed to stimulate IL-6 production in hACs (Fig-
ure 3a). The effects of IL-1F8 were mediated by IL-1Rrp2 and
could be completely blocked in presence of a polyclonal anti-
IL-1Rrp2 antibody (Figure 3b). Finally, the reported correlation
between IL-1F8 responsiveness and IL-1Rrp2 expression [16]
was supported by our observation that C28/I2 and SW1353
'chondrocyte-like' cell lines and human dermal fibroblasts in
which levels of IL-1Rrp2 mRNA were very low or absent did
not produce IL-6 in response to 5 µg/ml IL-1F8. In contrast,
incubation of these cells with 1 ng/ml of IL-1β stimulated IL-6
production (data not shown).
Debets and coworkers [5] reported that IL-1F5 could antago-
nize the effects of IL-1F9 when it was added at equimolar con-
centrations; we therefore tested the ability of recombinant
human IL-1F5 concentrations from 50 ng/ml to 5 µg/ml to
inhibit the effects of 5 µg/ml IL-1F8 on IL-6 production in
hACs. In these conditions, antagonism by IL-1F5 of the effects
of IL-1F8 was incomplete and not reproducible (data not
shown).
We then screened various cell types present in the inflamed
joint for endogenous IL-1F8 mRNA expression in vitro. By RT-
PCR, IL-1F8 expression was observed in hSFs when they
were treated for eight hours with IL-1β, TNF-α, or both (Figure
4a). By real-time PCR, we confirmed increased IL-1F8 mRNA
expression after 8 hours stimulation of hSFs with IL-1β alone,
IL-1β plus TNF-α, or IL-1α alone (Figure 4b). The increase in
IL-1F8 mRNA levels was strongest with stimulation by 1 ng/ml
IL-1β, as compared with 0.1 and 10 ng/ml (data not shown).
The steady state levels of IL-1F8 mRNA expression peaked at
8 hours (Figure 4c) in response to 1 ng/ml IL-1β, which is sim-Arthritis Research & Therapy    Vol 8 No 3    Magne et al.
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ilar to the time course of induction of endogenous IL-1β mRNA
by IL-1β in hSFs. In hACs expression of IL-1F8 mRNA was
constitutive and IL-1F8 levels were not affected by stimulation
of cells with IL-1β and TNF-α for 8 hours, whereas this treat-
ment consistently induced IL-1β gene expression (Figure 4d).
We also observed that the THP-1 monocyte cell line and Jur-
kat T-cell line expressed basal levels of IL-1F8 mRNA, but real-
time PCR experiments failed to detect IL-1F8 mRNA upregu-
lation in response to various stimuli, including IL-1β, TNF-α, IL-
4 and PMA (data not shown).
Next, we assessed IL-1F8 protein levels by ELISA in culture
supernatants of hSFs and hACs stimulated (or not stimulated)
with IL-1β for 48 or 72 hours. IL-1F8 protein levels were below
the limit of detection of the ELISA (19 pg/ml) in all samples.
We also measured IL-1F8 and IL-1β protein expression in syn-
Figure 2
Production of IL-6, IL-8 and nitric oxide by hSFs and hACs: effects of IL-1F8 and IL-1β Production of IL-6, IL-8 and nitric oxide by hSFs and hACs: effects of IL-1F8 and IL-1β. Shown is an analysis of the effects of IL-1F8 and IL-1β on 
production of (a) IL-6 and (c) IL-8 by hSFs, and of (b) IL-6, (d) IL-8 and (e) nitric oxide by hACs. Cells were treated with the indicated cytokine con-
centrations for 48 hours, as detailed under Materials and method. *P < 0.05 versus control; #P < 0.05 versus 0.1 ng/ml IL-1β; &P < 0.05 versus 500 
ng/ml IL-1F8, determined using analysis of variance. IL, interleukin; hAC, human articular chondrocyte; hSF, human synovial fibroblast.Available online http://arthritis-research.com/content/8/3/R80
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ovial biopsies of patients with various inflammatory arthritides
or OA (Table 2). As expected, IL-1β levels were elevated in
inflammatory arthritis synovial biopsies. On the contrary, IL-
1F8 protein levels were not increased in inflamed joint tissue.
IL-1F8 levels measured in synovial fluids were consistently
similar to or lower than those in matched serum samples
obtained from OA (n = 4) and RA (n = 4) patients, suggesting
that the joint itself is not a major source of IL-1F8 (data not
shown). We thus analyzed IL-1F8 levels in the serum of 28 RA
and 16 OA patients, 16 healthy controls, as well as 12
patients with septic shock. Serum levels of IL-1F8 were not dif-
ferent between the groups, although they tended to be higher
in healthy donors and in RA patients than in patients with OA
and septic shock (Figure 5). In healthy donors, RA and OA
patients, IL-1F8 levels did not correlate with serum IL-6 levels,
which were used as a marker of inflammation (data not
shown). Interestingly, we nevertheless observed high IL-1F8
levels (>50 pg/ml) in three out of 16 healthy donors, six out of
28 RA patients, two out of 16 OA patients, and one out of 12
septic patients (Figure 5).
We also examined serum IL-1F8 levels in RA patients (n = 9)
before and after anti-TNF treatment. Serum IL-1F8 levels
remained unchanged in RA patients after 8–36 weeks of anti-
TNF treatment, independently of the amelioration of clinical
symptoms (data not shown). Using a similar ELISA for mouse
IL-1F8, we measured IL-1F8 and IL-1β protein expression in
knees of mice with or without CIA (Table 2). Again, although
IL-1β levels were elevated in mouse joints during CIA, IL-1F8
levels were not. Serum IL-1F8 levels were below the limit of
detection of the ELISA in the serum of mice with CIA between
1 and 23 days after the onset of arthritis, as well as in control
naïve mice and in type II collagen-immunized mice exhibiting
no clinical signs of arthritis. Finally, in contrast to our observa-
tion in joints, we detected very high IL-1F8 protein levels in
mouse skin, which were further increased during PMA-
induced skin inflammation (Table 2). IL-1β levels increased in
parallel, although the amounts of protein detected in the skin
were much lower for IL-1β than for IL-1F8.
Discussion
There is currently a huge body of evidence indicating that IL-
1α, IL-1β, IL-1Ra and IL-18 are involved at some level in the
pathophysiology of RA (for review see [26,27]). We thus
hypothesized that some of the six new members of the IL-1
family might also play a role during RA. Therefore, we sought
to investigate the effects and the expression of new IL-1 family
members in joint cells.
Investigation of the in vitro effects of recombinant human IL-
1F8 revealed a direct correlation between IL-1Rrp2 expres-
sion and IL-1F8 responsiveness. Our results further support
findings indicating that IL-1Rrp2 is required for IL-1F8 signal-
ling [5,16]. Both hSFs and hACs produced inflammatory medi-
ators in response to IL-1F8, and stimulation of IL-6 and IL-8
production was somewhat stronger in hACs than in hSFs. To
our knowledge, the present study is the first to report respon-
siveness of nontransfected, primary cells to one of the recently
discovered IL-1 family members. In contrast, Wang and cow-
orkers [28] recently failed to detect an effect of recombinant
IL-1F8 on mixed glial cell cultures, which might be related to
low levels of IL-1Rrp2 expression. Indeed, the correlation
between IL-1F8 responsiveness and IL-1Rrp2 expression is
Figure 3
Production of IL-6 by hACs: effects of IL-1β, IL-1F8, heat-inactivated IL- 1F8 and anti-IL-1Rrp2 antibodies Production of IL-6 by hACs: effects of IL-1β, IL-1F8, heat-inactivated IL-
1F8 and anti-IL-1Rrp2 antibodies. (a) Analysis of the effects of IL-1β (1 
ng/ml), IL-1F8 and heat-inactivated IL-1F8 (5 mg/ml) on IL-6 production 
by hACs after 48 hours treatment, as detailed under Materials and 
method. (b) Analysis of the effects of anti-IL-1Rrp2 antibodies on IL-6 
production by hACs. Cells were stimulated or not (control) for 48 hours 
with IL-1F8 (5 mg/ml) or IL-1b (1 ng/ml), as indicated, in the presence 
(black columns) or absence (white columns) of blocking anti-IL-1Rrp2 
antibodies (10 mg/ml). P < 0.05 versus control; #P < 0.05 versus 5 
µg/ml IL-1F8, as determined by analysis of variance. hAC, human artic-
ular chondrocyte; IL, interleukin; IL-1Rrp2, IL-1 receptor related protein 
2.Arthritis Research & Therapy    Vol 8 No 3    Magne et al.
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supported by our observation that various cell lines in which
levels of IL-1Rrp2 mRNA were low did not produce IL-6 in
response to 5 µg/ml IL-1F8. In addition, our results indicate
that amounts of recombinant IL-1F8 required to stimulate
hSFs and hACs are higher than those of IL-1β, which is in
agreement with recent work reported by Towne and cowork-
ers [16]. Those authors reported significant stimulatory effects
at similar IL-1F8 concentrations as in the present study (500–
5,000 ng/ml).
Figure 4
Kinetics of IL-1β and IL-1F8 mRNA production by HSFs and hCAs in response to IL-1 and/or TNF-α Kinetics of IL-1β and IL-1F8 mRNA production by HSFs and hCAs in response to IL-1 and/or TNF-α. (a) Analysis of IL-1F8 mRNA levels in hSFs 
treated or not treated for 8 hours with IL-1β (1 ng/ml) and/or TNF-α (10 ng/ml), as detailed under Materials and method. A representative agarose 
gel electrophoresis of PCR products is shown. (b) Real-time PCR analysis of IL-1F8 mRNA levels in hSFs stimulated (black columns) or not stimu-
lated (white columns) for 8 hours with IL-1β (1 ng/ml) alone, IL-1β (1 ng/ml) plus TNF-α (10 ng/ml), or IL-1α (1 ng/ml) alone, as indicated. The 
amount of 28S rRNA was monitored as an internal control. The expression of IL-1F8 mRNA was corrected for 28S rRNA levels and the IL-1F8/28S 
ratios were normalized to the maximal value observed in each experiment, which was set to 100%. The results shown represent the mean ± standard 
error of data obtained with samples from three independent cultures. *P < 0.05 versus, as determined by analysis of variance. (c) Fold increase 
(after correction for 28S RNA levels) in IL-1β (dashed line) and IL-1F8 (solid line) mRNA levels after treatment of hSFs with 1 ng/ml IL-1β for the indi-
cated times, as revealed by real-time PCR analysis. Basal IL-1F8/28S and IL-1β/28S levels were respectively 6.4 and 20 (arbitrary units). (d) Real-
time PCR analysis of IL-1F8 and IL-1β mRNA levels in hACs stimulated (black columns) or not stimulated (white columns) with IL-1β (1 ng/ml) and 
TNF-α (10 ng/ml) for 8 hours. The amount of 28S rRNA was monitored as an internal control. The expression of IL-1F8 and IL-1β mRNA was cor-
rected for 28S rRNA levels and the IL/28S ratios were normalized to the maximal value observed in each experiment, which was set to 100%. The 
results shown represent the mean ± standard error of data obtained with samples from six independent cultures. *P < 0.05 versus, as determined by 
analysis of variance. hAC, human articular chondrocyte; hSF, human synovial fibroblast; IL, interleukin; RT-PCR, reverse transcriptase polymerase 
chain reaction; TNF, tumour necrosis factor.Available online http://arthritis-research.com/content/8/3/R80
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The need for high concentrations of recombinant IL-1F8 is not
understood, and thus far no biological effect of any of the new
IL-1 family members has been reported at below about 10-7
mol/l, as compared with about 10-11 mol/l for IL-1β and about
10-9 mol/l for IL-18. Interestingly, we recently observed that
transfection of IL-1Rrp2 expressing C20A4 chondrocytic cells
with an expression vector for human IL-1F8, which led to the
production of moderate quantities of IL-1F8 (50–200 pg/ml in
culture supernatants after 48 hours), efficiently induced IL-6
secretion in these cells, as compared with empty vector trans-
fected control cells (GP, FM and CG; unpublished observa-
tions). These observations suggest that endogenously
expressed IL-1F8 is active at much lower doses than recom-
binant IL-1F8, although the reason for this discrepancy is still
unknown and is currently under investigation. One hypothesis
is that post-translational modifications of the IL-1F8 protein
might be important for its biological activity and might be lack-
ing in recombinant IL-1F8 produced in E. coli. Levels of IL-1F8
detected for RA patients ranged up to 347 pg/ml in serum and
up to 176 pg/ml in synovial fluid, and according to our obser-
vations in C20A4 cells such concentrations of endogenously
produced IL-1F8 might be sufficient to trigger biological
effects in joint cells.
There is some controversy concerning the putative antagonist
effects of IL-1F5 [5,16]. Debets and coworkers [5] have
shown that IL-1F5 inhibits IL-1F9 induced nuclear factor-κB
activation in Jurkat T cells overexpressing IL-1Rrp2 [5], but
Towne and coworkers [16] did not observe consistent inhibi-
tory effects of IL-1F5 on IL-1F6-, IL-1F8-, or IL-1F9-induced
activation of nuclear factor-κB in the same cells. Although in
some experiments we observed antagonistic effects of IL-1F5
on the inflammatory action of IL-1F8 on hACs and hSFs, this
antagonism was inconsistent and incomplete. We currently
have no explanation for these nonreproducible effects. The
use of primary cultures may account for such findings in our
study but not in that of Towne and coworkers [16], who used
cell lines. It is also possible that recombinant IL-1F5 lacks con-
formational stability or post-translational modification, and that
this may alter its activity. The possible role played by IL-1F5
therefore remains unknown.
Investigation by RT-PCR of their expression in joints of mice
with CIA and in synovial tissue from patients with RA revealed
that, among the newly cloned IL-1 family members, only IL-1F8
was expressed in both mouse and human joints. Quantitative
PCR experiments demonstrated a significant upregulation of
IL-1F8 mRNA levels in cultured hSFs in response to IL-1β and/
or TNF-α. In contrast, IL-1F8 mRNA expression was constitu-
tive in hACs and was not affected by inflammatory stimuli. Sim-
ilarly, although monocyte and T-lymphocyte cell lines express
IL-1F8 mRNA to some extent, IL-1F8 levels were not increased
in response to a panel of stimuli. It has been reported that T
cells, either stimulated with anti-CD3 and/or anti-CD28 or left
unstimulated, do not express IL-1F8 mRNA, whereas lipopoly-
saccharide-treated monocytes do [10]. Despite IL-1F8 mRNA
expression, IL-1F8 protein expression was below the limit of
Figure 5
IL-1F8 protein levels in control individuals, patients with RA, OA and  septic shock IL-1F8 protein levels in control individuals, patients with RA, OA and 
septic shock. Shown are serum IL-1F8 protein levels in healthy donors 
(n = 16), patients with RA (n = 28) or OA (n = 16) patients, and 
patients with septic shock (n = 12), as determined by ELISA. Individual 
values (grey dots) and mean (stippled lines) ± standard error (black 
lines) are shown. Differences between the groups were not significant. 
ELISA, enzyme-linked immunosorbent assay; IL, interleukin; OA, oste-
oarthritis; RA, rheumatoid arthritis.
Table 2
IL-1F8 protein levels in mouse and human joint samples and in 
mouse skin
Samples Patients/animals IL-1F8 (pg/mg 
protein)
IL-1β (pg/mg 
protein)
Human 
synovium
OA (n = 4) 3.7 ± 1.4 3.6 ± 0.3
Inflammatory 
arthritis (n = 5)
3.9 ± 1.0 11.6 ± 5.7a
Mouse joint Naïve (n = 1) 2.8 2.3
Nonarthritic (n = 1) 2.7 4.5
CIA earlyb (n = 3) 2.2 ± 0.3 16.6 ± 1.2c
CIA lateb (n = 3) 4.5 ± 1.4 8.8 ± 0.8
Mouse skin Control (n = 3) 761.7 ± 313.4 16 ± 3
PMA (n = 3) 14569.1 ± 
3632.5d
28 ± 3d
IL-1F8 protein levels were determined using enzyme-linked 
immunosorbent assay. aP < 0.05 versus osteoparthritis (OA), as 
assessed using the Mann-Whitney test. bCollagen-induced arthritis 
(CIA) early: days 1–7 after the onset of arthritis; CIA late: days 8–21 
after onset of arthritis. cP < 0.05 versus late CIA, as assessed using 
analysis of variance. dP < 0.05 versus control, as assessed using 
analysis of variance.Arthritis Research & Therapy    Vol 8 No 3    Magne et al.
Page 10 of 11
(page number not for citation purposes)
detection of our assay in hSF and hAC culture supernatants.
In human OA and normal mouse joint tissue, IL-1F8 protein
expression levels were similar to those of IL-1β. However,
although IL-1β protein levels were increased in inflamed joints,
IL-1F8 levels were not. Interestingly, a very different situation
applied to mouse skin samples, in which IL-1F8 levels were
very high and further increased with inflammation. Further-
more, IL-1F8 levels in synovial fluids were similar to or lower
than those measured in matched serum samples, suggesting
that the joint itself is not a major source of IL-1F8. Indeed, in
the case of IL-6, for instance, which is produced in the joint,
synovial fluid concentrations are 100-fold to 1000-fold higher
than those measured in serum [29]. Serum levels of IL-1F8 did
not differ between healthy donors, and patients with RA, OA
and septic shock, and did not correlate with inflammatory sta-
tus. Interestingly, however, we observed high IL-1F8 levels in
several serum samples in all of these groups. The cause of
such high serum IL-F8 levels and the source of circulating IL-
1F8 are as yet unknown.
Conclusion
IL-1F8 exerts proinflammatory effects in primary human joint
cells. However, although IL-1F8 mRNA is expressed in hSF
and hAC, joint cells are not a major source of IL-1F8 protein.
Joint and serum IL-1F8 protein levels did not correlate with
inflammation, but IL-1F8 was elevated in some human serum
samples tested, including several samples from RA patients. It
remains to be determined whether, in some cases, circulating
IL-1F8 can contribute to joint inflammation in RA.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DM, GP, FM and DT-A performed the experiments concerning
the in vitro effects of IL-1F8, as well as the mRNA and protein
expression studies. SB, TD and MN collected and provided
human tissue, synovial fluid and serum samples. JLB and
MJHN produced the recombinant IL-1F proteins. DM, GP, SB,
PAG, MJHN and CG participated in the design of the study,
data analysis, and drafting and reviewing of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported the Swiss National Science Foundation 
(grants 3200-107592/1 to CG and 3100-064123.00/1 to PAG).
References
1. Arend WP, Malyak M, Guthridge CJ, Gabay C: Interleukin-1
receptor antagonist: role in biology.  Annu Rev Immunol 1998,
16:27-55.
2. Born TL, Thomassen E, Bird TA, Sims JE: Cloning of a novel
receptor subunit, AcPL, required for interleukin-18 signaling.  J
Biol Chem 1998, 273:29445-29450.
3. Barton JL, Herbst R, Bosisio D, Higgins L, Nicklin MJ: A tissue
specific IL-1 receptor antagonist homolog from the IL-1 clus-
ter lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities.  Eur
J Immunol 2000, 30:3299-3308.
4. Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, Zhou
H, Leiby KR, Holmgren LM, Gearing DP, Pan Y: Identification and
gene organization of three novel members of the IL-1 family
on human chromosome 2.  Genomics 2000, 66:213-216.
5. Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S, Wag-
ner J, Edwards G, Clifford T, Menon S, et al.: Two novel IL-1 fam-
ily members, IL-1 delta and IL-1 epsilon, function as an
antagonist and agonist of NF-kappa B activation through the
orphan IL-1 receptor-related protein 2.  J Immunol 2001,
167:1440-1446.
6. Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold
DE, Capper EA, Tal-Singer R, Wells GI, Doyle ML, Young PR:
Identification and initial characterization of four novel mem-
bers of the interleukin-1 family.  J Biol Chem 2000,
275:10308-10314.
7. Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace
AM, Hansen D, Schweighofer K, Mize NK, Ford JE: Cloning and
characterization of IL-1HY2, a novel interleukin-1 family
member.  J Biol Chem 2001, 276:20597-20602.
8. Mulero JJ, Pace AM, Nelken ST, Loeb DB, Correa TR, Drmanac R,
Ford JE: IL1HY1: a novel interleukin-1 receptor antagonist
gene.  Biochem Biophys Res Commun 1999, 263:702-706.
9. Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E,
Yansura D, Lewis L, Eigenbrot C, Henzel WJ, et al.: IL-1H, an
interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp.
Cytokine 2001, 13:1-7.
10. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims
JE: Four new members expand the interleukin-1 superfamily.
J Biol Chem 2000, 275:1169-1175.
11. Sims JE, Nicklin MJ, Bazan JF, Barton JL, Busfield SJ, Ford JE,
Kastelein RA, Kumar S, Lin H, Mulero JJ, et al.: A new nomencla-
ture for IL-1-family genes.  Trends Immunol 2001, 22:536-537.
12. Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE: Genomic
organization of the interleukin-1 locus.  Genomics 2002,
79:726-733.
13. Dunn EF, Gay NJ, Bristow AF, Gearing DP, O'Neill LA, Pei XY:
High-resolution structure of murine interleukin 1 homologue
IL-1F5 reveals unique loop conformations for receptor binding
specificity.  Biochemistry 2003, 42:10938-10944.
14. Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S,
Dinarello CA, Kim SH: A complex of the IL-1 homologue IL-
1F7b and IL-18-binding protein reduces IL-18 activity.  Proc
Natl Acad Sci USA 2002, 99:13723-13728.
15. Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto
A: Innate immunity mediated by the cytokine IL-1 homologue
4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and pro-
found antitumor immunity.  J Immunol 2003, 170:107-113.
16. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE: Interleukin
(IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-
1RAcP to activate the pathway leading to NF-kappaB and
MAPKs.  J Biol Chem 2004, 279:13677-13688.
17. Arend WP, Gabay C: Cytokines in the rheumatic diseases.
Rheum Dis Clin North Am 2004, 30:41-67. v-vi.
18. Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y,
F u j i k a w a  K ,  T a d a  N :  Macrophage- and neutrophil-dominant
arthritis in human IL-1 alpha transgenic mice.  J Clin Invest
2001, 107:1127-1135.
19. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T,
Asano M, Iwakura Y: Development of chronic inflammatory
arthropathy resembling rheumatoid arthritis in interleukin 1
receptor antagonist-deficient mice.  J Exp Med 2000,
191:313-320.
20. Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E: Altered
susceptibility to collagen-induced arthritis in transgenic mice
with aberrant expression of interleukin-1 receptor antagonist.
Arthritis Rheum 1998, 41:1798-1805.
21. Palmer G, Talabot-Ayer D, Szalay-Quinodoz L, Maret M, Arend
WP, Gabay C: Mice transgenic for intracellular interleukin-1
receptor antagonist type 1 are protected from collagen-
induced arthritis.  Eur J Immunol 2003, 33:434-440.
22. Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y: Suppression
of autoimmune arthritis in interleukin-1-deficient mice in
which T cell activation is impaired due to low levels of CD40
ligand and OX40 expression on T cells.  Arthritis Rheum 2002,
46:533-544.Available online http://arthritis-research.com/content/8/3/R80
Page 11 of 11
(page number not for citation purposes)
23. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY: Reduced
incidence and severity of collagen-induced arthritis in mice
lacking IL-18.  J Immunol 2001, 166:517-521.
24. Guicheux J, Palmer G, Relic B, Mezin F, Caverzasio J, Apostolides
P, Gauchat JF, Gabay C, Guerne PA: Primary human articular
chondrocytes, dedifferentiated chondrocytes, and synovio-
cytes exhibit differential responsiveness to interleukin-4: cor-
relation with the expression pattern of the common receptor
gamma chain.  J Cell Physiol 2002, 192:93-101.
25. Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR,
Abramson SB, Amin AR: Reversal of autocrine and paracrine
effects of interleukin 1 (IL-1) in human arthritis by type II IL-1
decoy receptor. Potential for pharmacological intervention.  J
Biol Chem 2000, 275:40307-40315.
26. Dayer JM: The pivotal role of interleukin-1 in the clinical mani-
festations of rheumatoid arthritis.  Rheumatology (Oxford)
2003, 42(Suppl 2):ii3-ii10.
27. Liew FY, Wei XQ, McInnes IB: Role of interleukin 18 in rheuma-
toid arthritis.  Ann Rheum Dis 2003, 62(Suppl 2):ii48-ii50.
28. Wang P, Meinhardt B, Andre R, Renshaw BR, Kimber I, Rothwell
NJ, Pinteaux E: The interleukin1-related cytokine IL-1F8 is
expressed in glial cells, but fails to induce IL-1beta signalling
responses.  Cytokine 2005, 29:245-250.
29. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C: CD14 is an
acute-phase protein.  J Immunol 2004, 172:4470-4479.